learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 801 resultslearn PTD-DBM
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn pyrrolidone carboxylic acid
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Research
5 / 485 resultsresearch Central Centrifugal Cicatricial Alopecia Associated With PDL1 Loss and Increased Expression of Caspase 3: A Case Series
CCCA may involve the PD1/PDL1 pathway and increased caspase 3, leading to permanent hair loss.
research Differences in cell subsets between sun-exposed and unexposed skin: preliminary single-cell sequencing and biological analysis from a single case
Sun-exposed skin shows different cell activity and gene expression, suggesting targets to prevent skin aging and cancer.
research 183 PD-1 regulatory network is upregulated in contact immunotherapy during alopecia areata treatment
Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
research Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions
Psoriasis may be chronic because it lacks certain immune system controls that prevent overreaction.
research Immunosenescence and inflammaging in Parkinson’s disease: mechanisms and therapeutic prospects
Age-related immune changes worsen Parkinson's disease, suggesting new treatment strategies.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PP405 - hair stem cell stimulation
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.